Skip to main content
  • Saved

made a Post

 

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

Source : https://doi.org/10.3389/fimmu.2020.00339

Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers. However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade is only 20 to 30%; its response rate in solid tumors is relatively low, and different degrees of side effects have occurred.

Sign In or Register Today to Access This Content